<DOC>
	<DOCNO>NCT02533401</DOCNO>
	<brief_summary>This study evaluate efficacy safety rituximab combination chemotherapy ( fludarabine cyclophosphamide ) participants B-cell CLL .</brief_summary>
	<brief_title>A Study Rituximab ( MabThera ) Participants With Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Adult participant great equal ( â‰¥ ) 18 year age Bcell CLL No previous treatment leukemia History malignancy within 2 year study entry , except adequately treat carcinoma situ cervix , basal squamous cell skin cancer , prostate cancer , breast cancer Comorbid condition require longterm ( great [ &gt; ] 1 month ) systemic corticosteroid study treatment Known infection hepatitis B C virus human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>